Leadership Changes at Oak Hill Bio
Oak Hill Bio, a clinical-stage company focusing on therapeutics for neonatology and rare diseases, has made significant updates to its executive leadership team. The company proudly announces the promotion of Josh Distler, J.D., to the role of Chief Executive Officer. Alongside this important change, Sharon Morriss, Ph.D., has been appointed as Chief Operating Officer, and Ike Greenstein, MBA, has been promoted to Chief Business Officer. Moreover, Oak Hill has expanded its Board of Directors with the addition of Jiaping Gu, Hussein Al-Mossawi, and Kim Davis.
Josh Distler: A Proven Leader
As a founding member of Oak Hill Bio, Josh Distler brings a wealth of experience from his previous positions as the company’s President and Chief Financial Officer. His background includes leadership roles at notable firms such as Athanor Capital and D. E. Shaw Group. Distler holds a bachelor’s degree from Harvard University and a law degree from Yale Law School, marking him as a versatile leader in the biotech landscape.
Exciting Partnership and Clinical Trials
In discussing his vision for Oak Hill Bio, Distler expressed enthusiasm for the company’s collaboration with Chiesi Group to advance the Phase 2b clinical study of their promising therapeutic candidate, OHB-607. The integration of experienced individuals like Sharon Morriss into the team strengthens the company's commitment to developing effective treatments for rare diseases. Morriss comes with a robust track record of leading successful clinical development teams, having held senior positions at leading biotech firms.
Sharon Morriss: Strengthening the Clinical Team
Morriss's extensive two-decade experience includes pivotal roles in advancing rare disease therapeutics through various phases of clinical development, emphasizing her contributions at Lung Therapeutics and Apellis Pharmaceuticals. She has been instrumental in driving FDA approvals for innovative therapies, showcasing her expertise in navigating the complexities of drug development.
The Role of Ike Greenstein
Ike Greenstein, another co-founder of Oak Hill, played a key role as Vice President of Corporate Development before his current elevation to Chief Business Officer. His financial acumen and strategic insights have contributed significantly to the company’s growth, forging partnerships and establishing foundations for future expansions.
New Additions to the Board
The board welcomes three new members whose diverse backgrounds and extensive experiences are set to enhance Oak Hill’s direction. Jiaping Gu, Ph.D., from Takeda Ventures, brings his deep understanding of biotech investments, while Hussein Al-Mossawi contributes his expertise in immunology from his role at Immunocore. Kim Davis adds a wealth of legal knowledge from her tenure in various executive positions within the biopharma sector.
Future Directions for Oak Hill Bio
Distler is optimistic about the future, stating, "We are thrilled to have Jiaping, Hussein, and Kim join our Board and look forward to working closely with them. Their combined drug development experience and diversity of valuable perspectives will help us navigate the next chapter of the Company's growth." With a commitment to developing life-changing treatments for preterm infants and patients with rare autoimmune diseases, Oak Hill Bio remains focused on expanding its pipeline of investigational therapeutics.
About Oak Hill Bio
Oak Hill Bio is dedicated to innovating therapeutics aimed at extremely preterm infants and individuals suffering from rare autoimmune conditions. The company operates both in the United States and the United Kingdom, advancing a robust pipeline of investigative medicines. The team’s expertise will drive the development of effective solutions meeting the needs of underserved patient populations.
Frequently Asked Questions
What recent leadership changes have taken place at Oak Hill Bio?
Oak Hill Bio has promoted Josh Distler to CEO, with Sharon Morriss appointed as COO and Ike Greenstein as Chief Business Officer.
What is Josh Distler's background?
Josh Distler is a co-founder of Oak Hill Bio, with extensive experience in biotechnology investments and leadership at prominent firms.
Who are the new members of the Board of Directors?
The new members are Jiaping Gu, Hussein Al-Mossawi, and Kim Davis, each bringing valuable expertise in drug development and biotech.
What therapeutic areas does Oak Hill Bio focus on?
Oak Hill Bio focuses on developing therapies for neonatology and rare autoimmune diseases.
How is Oak Hill Bio advancing its clinical trials?
Oak Hill Bio is collaborating with Chiesi Group to further develop its lead candidate, OHB-607, in a Phase 2b clinical study.
